I sold my shares at 6, got in last week. But what is amazing is that all this talk about Novartis. Novartis bought the rights to their tech thag creates monocyte islets from blood. This is related to diabities.
Novartis has not "purchased" anything related to Tovaxin or any MS stem cell tech. Read the press release from 2 weeks ago carefully. Novartis has no rights to Tovaxin.
From the PRess Release on 8/7/09 OXPA has entered into an exclusive agreement with Novartis, one of the world’s largest pharmaceutical companies, for the further development of Opexa’s novel stem cell technology. This technology, which has generated preliminary data showing the potential to generate monocyte derived islet cells from peripheral blood mononuclear cells, was in early preclinical development at Opexa.
More recently, Novartis and Opexa Therapeutics (OPXA) inked a deal giving Novartis control of Opexa’s stem cell program, including its Tovaxin MS therapy. Tovaxin is a personalized T-cell vaccine for relapsing remitting MS prepared by expanding specific subsets of myelin-reactive T-cells. Attenuated cells are reintroduced with a goal of setting up an anti-idiotype network to shift a TH1 mediated response to a Th2 response.
In 2008, the TERMS phase II study suggested the strong possibility of a therapeutic response similar to that seen with current platform therapies and with no significant side effects. Initiation of a phase III study in relapsing remitting MS is likely by early next year and will serve as a much bigger catalyst for Opexa than for Novartis.